Entity Details

Primary name PLPL2_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionQ96AD5
EntryNamePLPL2_HUMAN
FullNamePatatin-like phospholipase domain-containing protein 2
TaxID9606
Evidenceevidence at protein level
Length504
SequenceStatuscomplete
DateCreated2007-06-26
DateModified2021-06-02

Ontological Relatives

GenesPNPLA2

GO terms

Show/Hide Table
GOName
GO:0004806 triglyceride lipase activity
GO:0005654 nucleoplasm
GO:0005737 cytoplasm
GO:0005788 endoplasmic reticulum lumen
GO:0005789 endoplasmic reticulum membrane
GO:0005811 lipid droplet
GO:0005829 cytosol
GO:0005886 plasma membrane
GO:0006651 diacylglycerol biosynthetic process
GO:0010891 negative regulation of sequestering of triglyceride
GO:0010898 positive regulation of triglyceride catabolic process
GO:0016020 membrane
GO:0016021 integral component of membrane
GO:0019433 triglyceride catabolic process
GO:0019915 lipid storage
GO:0034389 lipid droplet organization
GO:0036155 acylglycerol acyl-chain remodeling
GO:0043687 post-translational protein modification
GO:0044267 cellular protein metabolic process
GO:0050253 retinyl-palmitate esterase activity
GO:0055088 lipid homeostasis

Subcellular Location

Show/Hide Table
Subcellular Location
Cell membrane
Lipid droplet

Domains

Show/Hide Table
DomainNameCategoryType
IPR002641 Patatin-like phospholipase domainDomainDomain
IPR016035 Acyl transferase/acyl hydrolase/lysophospholipaseFamilyHomologous superfamily
IPR033562 Patatin-like phospholipase domain-containing proteinFamilyFamily
IPR033903 Patatin-like phospholipase domain-containing protein 2DomainDomain

Diseases

Show/Hide Table
Disease IDSourceNameDescription
610717 OMIMNeutral lipid storage disease with myopathy (NLSDM)Neutral lipid storage disorder (NLSD) with myopathy but without ichthyosis. NLSDs are characterized by the presence of triglyceride-containing cytoplasmic droplets in leukocytes and in other tissues, including bone marrow, skin, and muscle. Individuals with NLSDM did not show obesity, in spite of a defect in triglyceride degradation in fibroblasts and in marked triglyceride storage in liver, muscles, and other visceral cells. The disease is caused by variants affecting the gene represented in this entry.